Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

A randomized controlled trial comparing pragmatic interventions to improve mammogram uptake in a non-compliant population.

Sasidharan Swarnalatha Lucky, Junxian Zhu, Samuel Guan Wei Ow et al. Jun 01, 2025 pp. 11008-11008 10.1200/jco.2025.43.16_suppl.11008

11008 Background: Despite over 20 years of a national breast cancer screening program, mammogram uptake in Singapore, a highly developed Asian country, re...

Effect of early palliative care integration on healthcare utilization in patients with newly diagnosed multiple myeloma.

Renato Verayo Samala, Daniel Paul Nurse, Xiaoying Chen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24042

e24042 Background: Owing to its incurable nature and cumulative toxicities from multiple treatment lines, managing symptoms and complications of multiple...

Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician’s choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer.

Simon Chowdhury, Alan Haruo Bryce, Karim Fizazi et al. Jun 01, 2025 pp. 5060-5060 10.1200/jco.2025.43.16_suppl.5060

5060 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) in men with BRCA-mutated chemotherapy-naïve metastatic cas...

Precision-calibrated LightGBM machine learning model to predict serious adverse events in oncology patients using FAERS.

Xiyu Zhao, Victor Yang, Jonathan Zou et al. Jun 01, 2025 pp. 12017-12017 10.1200/jco.2025.43.16_suppl.12017

12017 Background: The U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) is a large national repository capturing postmarketing dr...

Predicting the future: Socio-economic trends in Hodgkin versus non-Hodgkin lymphoma survival outcomes.

Mansi Mehta, Bolivia Crocete Aloysia Fernandes, Jaison Lawrence Alexander Santhi Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19036

e19036 Background: Lymphoma, categorized into Hodgkin (HL) and Non-Hodgkin (NHL), is the most common hematological malignancy worldwide. NHL is the eighth...

Activating AML patients through empowering cancer communication strategies.

Aicha M Diallo, Joelys Gonzalez Bisono, Tracy T. Rode Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18512

e18512 Background: As the number of people with Acute myeloid leukemia (AML) increases, patients and their care partners will need tailored information to...

Quality of life in a phase III study of prospective radiation therapy (IMRT) +/- cetuximab for locally advanced resected head and neck cancer: NRG/RTOG 0920.

Clement K. Gwede, Jonathan Harris, Mitch Machtay et al. Jun 01, 2025 pp. 11123-11123 10.1200/jco.2025.43.16_suppl.11123

11123 Background: We tested the primary question whether the addition of cetuximab to postoperative radiotherapy (IMRT) results in poorer patient reported...

Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.

Shuang Wei, Jiaqi Guo, Xueli Bai et al. Jun 01, 2025 pp. 8517-8517 10.1200/jco.2025.43.16_suppl.8517

8517 Background: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Chimeric antigen receptor (CAR)-T cell thera...

Race/ethnicity reporting and representation in clinical trials presented at the American Society of Clinical Oncology (ASCO) presidential plenaries from 2014 to 2024.

Bingtao Xiang, Ana Maria Avila Rodriguez, Aseem Aseem et al. Jun 01, 2025 pp. 11043-11043 10.1200/jco.2025.43.16_suppl.11043

11043 Background: The lack of appropriate racial and ethnic representation in life saving innovative trials has been linked to poor outcomes. To address t...

A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle.

Nehal J. Lakhani, William Bennion McKean, Ildefonso Ismael Rodriguez Rivera et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps3175

TPS3175 Background: The cyclin-dependent kinase (CDK)-RB-E2F axis forms the core transcriptional machinery driving cell cycle progression. Alterations in...

Antibody-drug conjugates and pneumonitis risk in breast cancer patients.

Anna Rachel Keating Franklin, Nancy Lunney, Kausik Maiti et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23312

e23312 Background: Antibody-drug conjugates (ADCs) are a novel treatment for breast cancer. Concerns have been raised about their potential to increase th...

The landscape of chromosomal instability in uterine leiomyosarcoma.

Sara Moufarrij, Qin Zhou, Alexia Iasonos et al. Jun 01, 2025 pp. 5607-5607 10.1200/jco.2025.43.16_suppl.5607

5607 Background: Uterine leiomyosarcoma (uLMS) has heterogeneous clinical presentations and outcomes. Although most uLMSs are associated with chromosomal...

Effect of multifunctional biocatalytic nanoenzyme AuC@SCOF-Mn on photodynamic-immunoactivation cascade response and antitumor efficacy in triple negative breast cancer.

Yu Min, Qian Li, Zhigong Wei et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13139

e13139 Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with no specific molecular targets and an immunosuppressive tumor microen...

Multisite validation of biomechanical computed tomography for osteoporosis assessment and fracture prediction in patients with high-risk or metastatic prostate cancer.

Samuel L. Washington, Janet M Chiang, Polly Teng et al. Jun 01, 2025 pp. 12044-12044 10.1200/jco.2025.43.16_suppl.12044

12044 Background: Long-term androgen deprivation therapy (ADT) among men with high-risk localized or metastatic prostate cancer (PCa) results in a 10-20%...

A meta-analysis of induction chemotherapy (ICT) followed by chemoradiotherapy for locally advanced cervical cancer: The role of ICT type and duration on efficacy outcomes.

Matheus de Oliveira Andrade, Otavio de Carvalho Modaffar Al Alam, Henrique Jin Son Kim et al. Jun 01, 2025 pp. 5539-5539 10.1200/jco.2025.43.16_suppl.5539

5539 Background: The treatment of locally advanced cervical cancer (LACC) is based on concomitant chemotherapy and radiotherapy (CCRT). While the recent i...

Experience of patients with HIV and squamous cell carcinoma of the anal canal (SCAC) treated with retifanlimab.

Jean-Philippe Spano, Jaume Capdevila, Frank Van Fraeyenhove et al. Jun 01, 2025 pp. 3521-3521 10.1200/jco.2025.43.16_suppl.3521

3521 Background: People living with HIV (PLHIV) usually have more advanced cancer at diagnosis and a higher cancer-related mortality, posing a significant...

Platform study of circulating tumor DNA–directed adjuvant chemotherapy in colon cancer (CLAUDIA Colon Cancer, KCSG CO22-12).

Yongjun Cha, Jin Won Kim, Taekeun Park et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps3645

TPS3645 Background: Tumor-informed circulating tumor DNA (ctDNA) analysis allows for the sensitive detection of minimal residual disease (MRD) and has the...

Comparable efficacy of venetoclax 50mg with posaconazole versus venetoclax 400mg in newly diagnosed AML patients: A prospective study of pharmacokinetics, toxicity, and clinical outcomes.

Gaurav Prakash, Rudra Narayan Swain, Anu Kumari et al. Jun 01, 2025 pp. 6530-6530 10.1200/jco.2025.43.16_suppl.6530

6530 Background: Metabolism of Venetoclax(VEN) by CYP3A enzymes gives a unique opportunity to administer it at a lower dose with a CYP3A inhibitor. Azoles...

Irinotecan liposome in Chinese patients with advanced pancreatic cancer: A prospective, multicenter, observational real-world study.

Jin Xu, Si Shi, Kuirong Jiang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16380

e16380 Background: The NAPOLI-1 study established the efficacy of irinotecan liposome combined with 5-FU/LV regimen in the second-line treatment of metast...

Comparison of sarcopenia diagnosis defined by low muscle mass measured by bioelectrical impedance analysis (BIA) or computed tomography (CT) in combination with low muscle strength in older adults with cancer.

Tomohiro F. Nishijima, Mototsugu Shimokawa, Keita Okahara et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23252

e23252 Background: International guidelines establish cutoff values for low muscle mass, as measured by DXA or BIA, as a component of sarcopenia definitio...

Association of baseline clinical factors with outcomes in patients with localized Ewing sarcoma treated on frontline trials with interval compressed chemotherapy (ICC): A report from the Children’s Oncology Group.

Ajay Gupta, Allen Buxton, Natalie DelRocco et al. Jun 01, 2025 pp. 10032-10032 10.1200/jco.2025.43.16_suppl.10032

10032 Background: Identifying clinical and biological factors associated with outcomes in localized Ewing sarcoma (ES) will enable risk-stratified clinica...

The impact of different formulations of goserelin on testosterone suppression in patients with prostate cancer: A real world observational research.

Sentai Ding, Zhenyan Song, Kejia Zhu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17160

e17160 Background: The purpose of androgen deprivation therapy (ADT) is to reduce and stabilise serum testosterone. However, dosing nonadherence for vario...

A phase 2 study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus cemiplimab plus placebo in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with positive PD-L1 expression.

Danny Rischin, Paolo Bossi, Nabil F. Saba et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps6112

TPS6112 Background: Concurrent blockade of lymphocyte activation gene 3 (LAG-3) may enhance the efficacy of anti–programmed cell death-1 (PD-1) therapies....

The role of metastatic burden in shaping mortality trends in patients with kidney cancer.

Sabah Mohib, Khadija Mohib, Fatima Hussain et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16536

e16536 Background: Kidney cancer, predominantly renal cell carcinoma (RCC), accounts for 2–3% of all adult cancers globally. The rising prevalence of risk...

Brain metastasis incidence with bireociclib in HR+/HER2- advanced breast cancer: Pooled analysis of BRIGHT-1 and BRIGHT-2 study.

Qingyuan Zhang, Jiayu Wang, Zhongsheng Tong et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13057

e13057 Background: Brain metastases (BM) significantly impact prognosis of patients (pts) with breast cancer (BC). Meta-analysis showed that hormone recep...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page